Patent Application Titled "Anti-Hla-Dq2.5 Antibody" Published Online (USPTO 20230118024).

Předmět:
Zdroj: Immunotherapy Weekly; 5/9/2023, p264-264, 1p
Abstrakt: "[3] The antibody of [2], wherein the gluten peptide is at least one, two, three, four, five, six, seven or all of the group consisting of a 33mer gliadin peptide, an alpha 1 gliadin peptide, an alpha 1b gliadin peptide, an alpha 2 gliadin peptide, an omega 1 gliadin peptide, an omega 2 gliadin peptide, a secalin 1 peptide and a secalin 2 peptide. "In certain embodiments, the gluten peptide is at least one, two, three, four, five, six, seven or all of the group consisting of a 33mer gliadin peptide, an alpha 1 gliadin peptide, an alpha 1b gliadin peptide, an alpha 2 gliadin peptide, an omega 1 gliadin peptide, an omega 2 gliadin peptide, a secalin 1 peptide and a secalin 2 peptide. "[4] The antibody of [2], wherein the antibody blocks the interaction between the HLA-DQ2.5/gluten peptide complex and an HLA-DQ2.5/gluten peptide-restricted CD4+ T cell. The antibody of claim 17, wherein the antibody blocks interaction between the HLA-DQ2.5/gluten peptide complex and an HLA-DQ2.5/gluten peptide-restricted CD4+ T cell. [Extracted from the article]
Databáze: Complementary Index